Dr. John C. Morris, MD - Mayo Clinic Staff | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Healthcare Professionals

John C. Morris, MD

Healthcare Professional
Mayo Clinic
200 First St. SW
Rochester, Minnesota, United States

John C. Morris is an endocrinologist and endocrine oncologist working both in the Divisions of Endocrinology and Medical Oncology at Mayo Clinic, Rochester, Minnesota. His areas of clinical focus include:

• Endocrine malignancies, both low risk and advanced (metastatic), including cancers of the thyroid, adrenals, parathyroid, and endocrine pancreas
• Thyroid nodules and goiter
• Thyroid ultrasound and biopsy
• Hyperthyroidism and hypothyroidism
• Pituitary and adrenal disorders

Dr. Morris received his medical degree from University of Tennessee, Memphis followed by residency and chief residency in internal medicine from University of Tennessee, Knoxville. He also completed his fellowship and research fellowship from Mayo Clinic College of Medicine.

Dr. Morris is also active in research and education providing mentorship to fellows and residents. He has published his work extensively in high-impact scientific and medical journals. In addition to clinical activities, Dr. Morris is involved in leadership of the American Thyroid Association in recent years and served as both President and Chief Operating Officer.

Currently, Dr. Morris is Chair at Laboratory Services Committee, American Thyroid Association; Symposium Organizer/Chair at American Thyroid Association; Chair at Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine; and Director at American Thyroid Association.


Representative Publications:

Heritability and Genetic Variance of Dementia With Lewy Bodie

Clinical, Pathophysiological and Genetic Features of Motor Symptoms in Autosomal Dominant Alzheimer’s Disease

Comparison of Pittsburgh Compound B and Florbetapir in Cross-Sectional and Longitudinal Studies

Emerging Cerebrospinal Fluid Biomarkers in Autosomal Dominant Alzheimer’s Disease